Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

This study is testing a combination of two drugs — abemaciclib (a cell-cycle inhibitor) and bicalutamide (a hormone blocker) — for women with androgen receptor-positive (AR+), HER2-negative metastatic breast cancer. This targets a specific molecular feature of the cancer to block its growth. **You may be eligible if...** - You are a woman 18 or older with metastatic or locally advanced HER2-negative breast cancer - Your cancer tests positive for the androgen receptor (AR+ on biopsy) - Your cancer is measurable or evaluable on imaging - You are in reasonably good physical health (ECOG 0–2) - Your life expectancy is at least 12 weeks - If you have ER+ or PR+ cancer, you have already received prior hormonal therapies **You may NOT be eligible if...** - Your cancer is HER2-positive - You have significant heart disease or poor organ function - You are pregnant or breastfeeding - You have active brain metastases requiring treatment - You have had prior treatment with a CDK4/6 inhibitor (like palbociclib or ribociclib) Talk to your doctor to see if this trial is right for you.